Clover Health Investments, Corp. (CLOV)
NASDAQ: CLOV · Real-Time Price · USD
3.590
-0.110 (-2.97%)
At close: Mar 28, 2025, 4:00 PM
3.570
-0.020 (-0.56%)
After-hours: Mar 28, 2025, 7:55 PM EDT
Clover Health Investments Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Clover Health Investments stock have an average target of 4.83, with a low estimate of 4.00 and a high estimate of 6.00. The average target predicts an increase of 34.54% from the current stock price of 3.59.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Clover Health Investments stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 0 | 1 | 1 | 1 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 2 | 2 | 2 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4.2 → $4.5 | Strong Buy | Maintains | $4.2 → $4.5 | +25.35% | Mar 3, 2025 |
Craig-Hallum | Craig-Hallum | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +67.13% | Dec 17, 2024 |
UBS | UBS | Hold Initiates $4 | Hold | Initiates | $4 | +11.42% | Oct 7, 2024 |
Citigroup | Citigroup | Hold Maintains $1 → $1.5 | Hold | Maintains | $1 → $1.5 | -58.22% | Aug 11, 2023 |
Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4 → $3 | Strong Buy | Maintains | $4 → $3 | -16.43% | Mar 6, 2023 |
Financial Forecast
Revenue This Year
1.87B
from 1.37B
Increased by 36.58%
Revenue Next Year
2.12B
from 1.87B
Increased by 13.25%
EPS This Year
-0.14
from -0.09
EPS Next Year
-0.11
from -0.14
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 2.3B | 2.4B | 2.6B | ||
Avg | 1.9B | 2.1B | 2.6B | ||
Low | 1.5B | 1.8B | 2.5B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 70.1% | 28.6% | 24.1% | ||
Avg | 36.6% | 13.2% | 20.6% | ||
Low | 8.3% | -4.6% | 15.8% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.07 | -0.08 | 0.11 | ||
Avg | -0.14 | -0.11 | 0.10 | ||
Low | -0.18 | -0.15 | 0.10 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.